Why the study?
Does saxagliptin reduce ischemic events in patients with Type 2 Diabetes Mellitus?
Does saxagliptin reduce ischemic events in patients with Type 2 Diabetes Mellitus?
Saxagliptin does not reduce ischemic events in patients with type 2 diabetes but increases the risk of hospitalization for heart failure.
No ischemic benefit with saxagliptin in T2DM; confirms neutral CV ischemic safety with HF hospitalization signal.
DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
No takes yet. Share an insight, caveat, or question.
Scirica et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: